Global blood therapeutics, inc. (GBT)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss

-290,869

-266,766

-219,993

-198,513

-181,560

-174,193

-166,243

-151,733

-135,248

-117,024

-102,979

-95,408

-89,200

-82,468

-70,846

-64,624

-55,543

-46,360

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

8,749

8,605

8,392

7,452

6,031

4,607

3,159

2,392

1,995

1,658

1,327

1,248

1,251

1,160

1,108

1,004

932

873

0

0

0

Amortization (accretion) of premium (discount) on marketable securities

1,593

2,057

2,159

1,972

1,319

661

83

-431

-613

-704

0

0

0

-

-

-

-

-

-

-

-

Non-cash interest expense

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of operating lease right-of-use assets

1,920

1,327

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

52,565

45,651

40,382

34,897

31,749

30,080

27,293

24,032

18,892

13,682

12,292

11,737

10,542

9,235

7,376

5,098

4,168

3,223

0

0

0

Loss from disposal of fixed assets, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-33

0

0

0

Changes in operating assets and liabilities:
Accounts receivables

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventories

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

3,281

3,085

3,221

22

1,774

2,500

3,479

1,725

1,185

1,856

3,150

2,884

1,421

761

82

1,230

1,153

87

0

0

0

Other assets, current

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-22

0

0

0

Accounts payable

5,794

4,499

1,934

2,990

-275

-1,285

1,579

-1,569

4,296

2,771

1,605

500

-1,064

1,066

376

3,199

3,238

2,705

0

0

0

Payable due to related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Accrued liabilities

17,053

24,706

7,706

12,273

8,793

8,031

8,262

3,799

923

3,280

948

2,373

3,462

1,794

2,652

2,579

2,894

2,834

0

0

0

Accrued compensation

5,641

7,543

3,272

2,001

906

1,457

1,658

1,748

1,948

3,612

2,170

1,636

1,060

2,725

1,903

2,074

1,173

1,395

0

0

0

Operating lease liabilities

2,931

893

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities

0

-

-

-

-809

-420

920

981

778

376

-80

-81

-64

-60

-43

-30

-29

-25

0

0

0

Net cash used in operating activities

-232,723

-194,417

-165,653

-142,728

-138,925

-135,375

-127,159

-121,869

-107,213

-93,022

-87,717

-80,913

-75,664

-67,723

-57,318

-47,350

-39,463

-30,890

0

0

0

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment

5,928

3,460

1,076

2,072

4,378

4,824

6,274

5,826

3,429

3,101

2,019

972

1,148

1,352

1,324

1,393

1,202

993

0

0

0

Purchase of marketable securities

328,678

434,919

0

0

0

-

-

-

-

127,724

0

0

0

-

-

-

-

-

-

-

-

Maturities of marketable securities

449,477

361,473

307,127

226,142

203,503

181,997

152,598

139,993

128,789

96,000

0

0

0

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

114,916

-76,861

-125,778

-219,999

-326,382

-184,157

-113,485

18,571

76,202

-35,000

-183,131

-198,548

-176,102

-106,852

-1,324

-1,393

-1,202

-993

0

0

0

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock in public offering, net

-

219,443

360,825

355,371

162,768

396,501

351,449

351,449

351,190

231,955

0

0

0

-

-

-

-

-

-

-

-

Payment of deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Proceeds from sale of restricted stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,108

0

0

0

Proceeds from issuance of common stock in settlement of employee stock purchase plan and exercise of stock options

14,900

13,857

6,837

8,039

6,773

7,669

7,548

6,134

5,637

3,892

3,189

2,396

1,822

1,240

1,118

532

539

45

0

0

0

Payments of debt issuance costs

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repurchases of unvested restricted stock purchases

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

67

0

0

0

Tax paid related to net share settlement of equity awards

9,030

7,617

3,514

2,831

1,534

6,252

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

276,496

298,158

364,144

360,567

167,995

397,906

352,735

351,520

350,764

235,188

138,066

142,198

254,432

118,145

117,982

240,078

128,849

128,316

0

0

0

Net increase (decrease) in cash, cash equivalents and restricted cash

158,689

26,880

72,713

-2,160

-297,312

78,374

112,091

248,222

319,753

107,166

-132,782

-137,263

2,666

-56,430

59,340

191,335

88,184

96,433

0

0

0

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:
Leasehold improvements paid for by landlord

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of Series A redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,180

0

0

0

Accrued purchase of property and equipment

495

78

2,297

1,596

-893

48

-735

105

2,513

1,536

-35

131

181

114

0

0

0

-

-

0

0

Accrued issuance costs

0

-

-

0

0

-

-

-

0

-

-

-

0

-

-

-

-

-

0

0

0